Has it been tested in people?

The completed study tested a different substance

CB4211 is a changed version of MOTS-c made for research. It is a different substance from MOTS-c.

Its registered early human study was completed in 2021, according to ClinicalTrials.gov.

The company reported findings for CB4211, but they had not been published in a medical journal as of September 30, 2026.

A result for CB4211 cannot be counted as a result for MOTS-c.

The MOTS-c record has no results

The MOTS-MET study record describes a trial of MOTS-c in China for adults with prediabetes and extra weight.

Prediabetes is raised blood sugar below the diabetes range.

On September 30, 2026, it was listed as looking for people to join and had no results to read.

A registry entry describes a study plan; it does not establish a treatment benefit.

A listed trial still needs results

FDA, the US drug agency, did not mention the registered MOTS-MET trial in its written review.

The trial record had been posted before that memo.

As of September 30, 2026, it was not clear why FDA’s review left out that trial. The trial listing still had no results showing whether the injections helped people.

Ask for the trial’s results when someone cites it as proof that the shots work. A listing alone cannot answer that question.

Read the result, not just the trial title

Ask what substance was tested, what the study found and where its results were published. A treatment claim needs more than a link to a study plan.

Keep this in mind

As of September 30, 2026, the completed study tested a changed version of MOTS-c and remained unpublished. The trial of MOTS-c itself had no results to read.

A question to take

Is the cited trial about MOTS-c itself, and are its results published?